Navigation Links
Amgen Announces 2012 Third Quarter Dividend
Date:7/19/2012

THOUSAND OAKS, Calif., July 19, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.36 per share dividend for the third quarter of 2012. The dividend will be paid on Sept. 7, 2012, to all stockholders of record as of the close of business on Aug. 16, 2012. 

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a ... with a flexure design that ensures high alignment accuracy by preventing unwanted shaft ... ideally suited where extreme precision is required, such as in medical equipment, laboratory ...
(Date:11/30/2016)...  The Allen Institute for Cell Science has ... available collection of gene edited, fluorescently tagged human ... structures with unprecedented clarity. Distributed through the Coriell ... a crucial first step toward visualizing the dynamic ... human cells healthy and what goes wrong in ...
(Date:11/30/2016)... Part of 5m$ Investment in Integrated Drug Discovery ... , ... announced that it had successfully completed the expansion of their ... the Screening Collection to over 400,000. The new compounds were ... company. This expansion, complemented by new robotics and compound management ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... On 28 ... and symbols for four elements: nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson ... of public review, the names earlier proposed by the discoverers have been approved by ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
Breaking Biology News(10 mins):